Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • EPI-001: Androgen Receptor N-Terminal Domain Inhibitor Workf

    2026-06-02

    EPI-001: Advanced Workflows for Androgen Receptor N-Terminal Domain Inhibition

    Principle and Setup: Targeting the Androgen Receptor N-Terminal Domain

    The androgen receptor (AR) plays a pivotal role in the progression of prostate cancer and select subtypes of breast cancer, notably triple-negative breast cancer (TNBC). Traditional AR antagonists, such as enzalutamide, target the ligand-binding domain, but resistance often arises through AR splice variants (e.g., ARv7) that lack this domain and remain constitutively active. EPI-001, supplied by APExBIO, is a first-in-class small-molecule inhibitor that binds the N-terminal domain of the AR, disrupting critical protein-protein interactions required for AR transcriptional activity. This mechanism enables robust inhibition of both full-length AR and its splice variants, addressing a key limitation of earlier therapies in both prostate cancer and AR-driven TNBC models.

    Step-by-Step Workflow: Experimental Protocols for EPI-001

    Leveraging EPI-001 for in vitro and in vivo studies requires careful consideration of solubility, dosing, and readout selection. The following protocol parameters are distilled from recent literature, product specifications, and best practices in AR pathway research.

    Protocol Parameters

    • Compound solubilization: Dissolve EPI-001 in DMSO at 10–20 mM stock concentration; sonicate for 5–10 minutes if necessary, ensuring complete dissolution as per the product information.
    • In vitro dosing: Treat androgen-sensitive or CRPC cell lines (e.g., LNCaP, C4-2, LAPC4, MDA-MB-231) with EPI-001 at 10–50 μM final concentration for 24–72 hours, monitoring dose-dependent inhibition of AR mRNA and protein expression.
    • In vivo administration: For murine xenograft models, administer EPI-001 intravenously at 10–30 mg/kg, 2–3 times per week for 2–4 weeks, as used in xenograft regression and prostate weight reduction studies.

    Key Innovation from the Reference Study

    The reference study delivers a significant advance by directly demonstrating that AR and ARv7 expression in TNBC patients correlates with poor prognosis and increased metastasis risk. Using MDA-MB-231 cells, the study uniquely compares EPI-001 and enzalutamide, showing that only the N-terminal domain inhibitor EPI-001 effectively abates both AR-driven transcription and downstream metastatic pathways—including suppression of NF-κB and c-Myc, and modulation of EMT markers. For research workflows, this finding supports prioritizing EPI-001 when dissecting AR/ARv7-driven pathways or screening for anti-metastatic interventions, especially in models where ARv7 is present and ligand-binding domain antagonists are ineffective.

    Enhanced Protocols: Applied Use-Cases and Workflow Optimization

    Recent studies and workflow guides, such as EPI-001: Androgen Receptor N-Terminal Domain Inhibitor Workflows, provide practical advice on integrating EPI-001 into standard and advanced protocols:

    • Cell line selection: Utilize AR-positive cell lines (LNCaP, C4-2, LAPC4, MDA-MB-231) to capture both androgen-dependent and resistant phenotypes. For ARv7 studies, confirm variant expression by RT-qPCR or immunoblotting prior to treatment.
    • Assay endpoints: Measure AR transcriptional activity via luciferase reporter assays (ARE-luc), AR protein level by Western blot, and cell viability via MTT or CellTiter-Glo. For EMT/metastasis studies, assess markers such as E-cadherin, N-cadherin, ROCK1/2, and c-Myc by immunoblot or ELISA, as detailed in the reference study.
    • Combination studies: When modeling resistance, co-treat with enzalutamide and EPI-001 to distinguish LBD-dependent and NTD-dependent AR signaling. This approach is supported by complementary findings in Targeting AR and ARv7 in TNBC, which extends the reference study’s implications to broader breast cancer research.

    Troubleshooting & Optimization Tips

    • Compound precipitation: Given EPI-001’s low water solubility, always dilute DMSO stocks into pre-warmed (37°C) culture media under vigorous mixing. Avoid exceeding 0.5% DMSO final concentration to minimize cytotoxicity.
    • Stability considerations: Prepare fresh working solutions prior to each experiment, as EPI-001 stability in solution is optimal for short-term use only. Store powder at -20°C and avoid repeated freeze-thaw cycles.
    • Off-target effects: Validate AR pathway specificity by including AR-negative cell lines as negative controls. Cross-confirm findings with AR knockdown (siRNA) or CRISPR knockout approaches where feasible.
    • Batch variability: Use high-purity lots (>98% by HPLC/NMR) from reputable suppliers like APExBIO to ensure reproducibility across experiments.

    Comparative Advantages and Advanced Applications

    EPI-001’s ability to inhibit both ligand-dependent and independent AR signaling distinguishes it from classical antiandrogens. In prostate cancer models, it induces a dose-dependent reduction in AR mRNA and protein, leading to robust inhibition of cell proliferation and significant tumor regression (see product page). In TNBC models, EPI-001 uniquely suppresses key regulators of metastasis—such as downregulating NF-κB and c-Myc, and shifting EMT markers—whereas LBD-targeted agents like enzalutamide are less effective against ARv7-expressing cells (reference study).

    This approach is complemented by findings in Targeting AR and ARv7 in TNBC: EPI-001 as a Molecular Inhibitor, which underscores EPI-001’s role in modulating metastatic and EMT pathways, and in EPI-001: Androgen Receptor N-Terminal Domain Inhibitor for Advanced Cancer Models, which demonstrates the compound’s utility in both prostate and breast cancer xenograft systems. Together, these studies establish EPI-001 as a versatile tool for dissecting AR-driven oncogenic processes across cancer types.

    Future Outlook: Implications for Cancer Research

    The emergence of ARv7 and other ligand-binding domain-deficient variants necessitates next-generation inhibitors such as EPI-001 that directly target the AR N-terminal domain. The reference study suggests that comprehensive AR/ARv7 inhibition not only stymies tumor cell proliferation but also profoundly alters metastatic potential and epithelial-mesenchymal plasticity, opening new research directions in both prostate cancer and AR-positive TNBC.

    As protocols mature and more advanced readouts (e.g., single-cell transcriptomics, real-time EMT tracking) are adopted, EPI-001 will continue to underpin translational studies aimed at overcoming antiandrogen resistance. While off-target and pharmacokinetic challenges remain, ongoing refinements in formulation and delivery are expected to further enhance its utility in preclinical research.

    In summary, EPI-001—supplied by APExBIO—enables rigorous, reproducible interrogation of AR signaling in both classical and resistant cancer contexts. Its unique mechanism of action, robust inhibition profile, and compatibility with diverse experimental workflows make it an indispensable component of modern AR biology research.